Mindblown: a blog about philosophy.
-

Apple, NVIDIA, Amazon Stocks: Analysts Stay Bullish
Despite some bumps along the way, Apple, NVIDIA, and Amazon continue to have plenty of believers on Wall Street.
-

Ciena Q3 Earnings Beat Highlights Next Phase of AI Infrastructure Boom
Ciena sits in a part of the AI supply chain where spending is becoming physical, and Q3 showed that customers are already putting money behind it.
-

Snowflake’s Q2 Blowout Just Rewrote the Growth Story
Snowflake’s AI narrative is real, but the company has to show continuing growth without eventually running into the law of large numbers.
-

Palo Alto Networks Sees Growth as AI Creates New Cybersecurity Threats
Palo Alto Networks continues to benefit from growing concerns about artificial intelligence (AI) and the new cybersecurity risks that come with it.
-

AST SpaceMobile (ASTS) Stock’s Q2 Meltdown May Offer a Contrarian Trade
Although AST SpaceMobile’s latest earnings report left investors disappointed, the red ink could open up a speculative opportunity for ASTS stock options.
-

Why The $187 Credo’s Post-Earnings Selloff Doesn’t Change My Thesis
If Credo grows at this pace as optics becomes a second engine, the selloff will look like the market giving investors time to recognize what it is becoming.
-

Insider Buying: Why Executives Are Buying into These 3 Stocks
For investors, insider buying is one piece of the puzzle—alongside earnings, valuation, growth prospects and risks, not a standalone reason to buy a stock.
-

PANW Earnings: Is the Software Selloff Dragging Down a Great Quarter?
The market had already started cutting exposure to expensive software before PANW reported. The strong earnings failed to reverse that pressure.
-

Dell Explodes Higher as AI Server Demand Drives Record Q2 2027 Results
Dell Technologies delivered quarterly results thar suggest the company is increasingly positioned as a major beneficiary of the AI spending boom.
-

Medtronic Earnings: Fundamentals Finally Match Perception
Medtronic has long been treated as a slow-growth medtech name. This earnings report argues otherwise, at least for now
Got any book recommendations?